Aarhus research project receives major million-dollar investment for the treatment of rare immune diseases
A new research project based at Aarhus University and Aarhus University Hospital will pave the way for more precise and individualized treatment of patients with congenital immunodeficiencies. Innovation Fund Denmark has just invested DKK 24.6 million in the project, which has been named GENESCURE.
The aim of GENESCURE is to develop new treatment methods based on the patient’s own stem cells. Through advanced gene editing, researchers will attempt to correct the genetic errors that underlie the diseases and thereby restore a normally functioning immune system.
“The support from Innovation Fund Denmark is crucial in our work to bring research from the lab to the patient. We now have the opportunity to take a big step towards offering tailored treatments to patients who previously had limited treatment options,” says Chief Physician and Clinical Associate Professor Bjarne K. Møller. Møller to Aarhus University’s website.
The treatment being tested in the project is based on a method called autologous transplantation. Here, the patient’s own blood-forming stem cells are extracted, genetically modified in the laboratory and returned to the body with the aim of restoring immune system function.
The three-year project brings together researchers from both the Department of Biomedicine and the Department of Clinical Medicine at Aarhus University and specialists from a number of clinical departments at Aarhus University Hospital.
Indlægget Aarhus research project receives major million-dollar investment for the treatment of rare immune diseases blev først udgivet på TechSavvy.